anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A &#39;lipidosome Chinese traditional medicine membranous plaster&#39; relates to a new dosage form absorbed by skins with Chinese and western medicine combined for external use. The medicine is absorbed by skins and then goes into the blood circulation to act on tissues and organs in the body or the body surface. The lipidosome Chinese traditional medicine membranous plaster is characterized in that the lipidosome Chinese traditional medicine membranous plaster uses western medicine encapsulated by the lipidosome to provide treatment aiming at the pathogen and pathological changes, simultaneously provide diagnosis and treatment against the general symptoms based on an overall analysis of the illness and the patient&#39;s conditions, balance Qi and blood and Yin Yang and zang-fu functions and increase the anti-disease immunity and repairing capability of the body itself, thus treating both principal and secondary aspects of diseases and effectively curing various annoyances (including tumors). By selecting different Chinese traditional and western medicines and different dosages based on pathogenic factors and pathological changes of different diseases, the &#39;lipidosome Chinese traditional medicine membranous plaster&#39; is made into membranous plaster medicine for external use. By externally applying the lipidosome Chinese traditional medicine membranous plaster on the corresponding position or the relevant acupuncture points of channels and collaterals of the body surface, various tumors and annoyances can be effectively treated. The lipidosome Chinese traditional medicine membranous plaster is composed of western medicines encapsulated and Chinese traditional mixed plaster [(a certain proportion of extractions from Chinese traditional medicines or mixture of effective composition ingredients or Chinese traditional medicine powder)] together with (a certain proportion of film former) and (a certain proportion of plasticizer) which are mixed uniformly and the mixtures are put in.
PROBLEM TO BE SOLVED: To obtain the subject therapeutic agent comprising an extract of black cohosh root as active ingredient, suppressing bone absorption by parathyroid hormone and reduction in bone density, having no adverse effect, useful for treating osteoporosis, hypercalcemia, etc. SOLUTION: This therapeutic agent comprises an extract of black cohosh root an active ingredient. Cimicifuga foetida L. produced in SISENSYOU in China, etc., are preferable as the black cohosh root. The extract of black cohosh root is preferably obtained by extracting rhizome of black cohosh root with methanol under heating, distilling away methanol from the extracted solution and extracting the residue with ethyl acetate. The extract with ethyl acetate is further purified by column chromatography and collected to give a terpene compound of formula I (R&lt;1&gt; is β-xylosyl; R&lt;2&gt; is CH2 or a group of formula II) showing strongly treating action on bone. The compound may be used as the active ingredient. A dose of the extract of black cohosh root is preferably 0.1-3 g/kg in oral administration per adult.  A dose of oral administration per adult is preferably 0.01-0.3g/kg in the case of the terpene compound as the active ingredient.
1. Use of treosulfan for the preparation of a pharmaceutical composition for conditioning therapy over a period of 2 to 7 days while administering of the common dose, of at least, 20 g/m&lt;2&gt; body surface area before allogenic transplantation of bone marrow or haematopoietic stem cells. 2. Use according to Claim 1, characterized in that the total dose amounts to 20 to 60 g/m&lt;2&gt; body surface area. 3. Use according 2 Claim 2, characterized in that the total dose amounts to 30 g/m&lt;2&gt; body surface area. 4. Use according to Claim 2, characterized in that the total dose amounts to 42 to 48 g/m&lt;2&gt; body surface area. 5. Use according to Claims 1 to 4, characterized in that the conditioning therapy takes place over a period of 3, 5 or 7 days. 6. Use according to Claims 1 to 4, characterized in that the conditioning therapy takes place in the form of a continuous infusion. 7. Use according to Claims 1 to 4, characterized in that the conditioning therapy takes place in the form of daily individual doses. 8. Use according to Claim 4, characterized in that the pharmaceutical composition is formulated so that it is suitable for the infusion of treosulfan over a period of 2 to 7 days, in each ease for a period of 0.5 to 24 hours per day. 9. Use according to Claims 1 to 8, characterized in that treosulfan is used with at least one further chemotherapeutic agent and/or immunosuppressive agents. 10. Use according to Claim 9, characterized in that the pharmaceutical composition is a combination preparation. 11. Use according to Claim 10, characterized in that the chemotherapeutic agent is a cytostatic agent. 12. Use according to Claim 11, characterized in that the cytostatic agent is selected from the group consisting of cyclophosphamide, thiotepa, melphalan, carboplatin or fludarabine. 13. Use according to Claims 9 to 12, characterized in that the immunosuppressive agents are immunosuppressive antibodies. 14. Use according to Claims 9 to 12 for conditioning therapy with additional whole-body irradiation of the patient. 15. Use according to Claim 12, characterized in that the cytostatic agent is cyclophosphamide, and the pharmaceutical composition is formulated so that it is suitable for the administration of 14 to 16 g treosulfan/m&lt;2&gt; body surface area on each of 3 consecutive days, and of 60 to 100 mg cyclophosphamide/kg body weight on each of the following 2 days.
Described are compounds of formulae I and II, wherein: R is H, halo, hydroxy, amino, or optionally substituted alky, and R&#39; is H, halo, amino, or optionally substituted alkyl. Also described is the isolated polypeptide shown in SEQ. ID. NO. 1, which may be used to produce the compounds of formulae I and II. The compounds of formulae I and II are used in the manufacture of medicaments for the treatment of bacterial or fungal infections.
PURPOSE: To inexpensively obtain an immunopotentiator having high macrophage activating action and bacterial infection defensive action, thus useful in feed for livestock, fish, etc., containing, as active ingredient, a protein component obtained by heating and deactivating yeast cells followed by enzymatic treatment of the deactivated cells. CONSTITUTION: This immunopotentiator contains, as active ingredient, a protein component which is obtained by heating and deactivating yeast cells (pref. Torulaspora or Saccharomyces) followed by making a cell wall digesting enzyme and a protease act on the deactivated cells. The yeast is pref. obtained by culturing the original cells in a sulfite pulp waste liquor medium because of saving cost and high activity. It is preferable that the heating and deactivating operation be made at 90-100 deg.C for 10min. The enzymatic treatment is preferably performed by the addition of both the above enzymes at 0.2-3wt.%, respectively, for 1-30h. It is preferable thgat &gt;=15wt.% of the whole protein in the yeast cells be extracted.
The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin transfected with exogenous genetic material (DNA) which encodes a desired (e.g. a therapeutic) product or is itself a desired (e.g. therapeutic) product, methods by which primary and secondary cells are transfected to include exogenous genetic material, including DNA targeting by homologous recombination, methods of producing clonal cell strains or heterogenous cell strains, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells. The present invention includes primary and secondary somatic cells, such as fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial cells, neural cells, formed elements of the blood, muscle cells, other somatic cells which can be cultured and somatic cell precursors, which have been transfected with exogenous DNA which is stably integrated into their genomes or is expressed in the cells episomally. The exogenous DNA either encodes a product, such as a translational product (e.g. a protein) or a transcriptional product (e.g. a ribozyme or an anti-sense nucleic acid sequence) which is a therapeutic product or is itself a therapeutic product (e.g. DNA which binds to a cellular regulatory protein or alters gene expression). &lt;IMAGE&gt;
The present invention started when a λgt11 cDNA library of normal human melanocytes was screened with antibodies directed against purified hamster tyrosinase. Two important cDNA clones were isolated: cDNA λmel 34 and λmel 17-1. It is concluded that λmel 34 contained cDNA encoding human tyrosinase. Moreover, the cDNA gene for human tyrosinase was recovered from the λmel 34 and can be used for many purposes including the production of pure human tyrosinase. This gene and its promoter are characterized herein. Studies suggested that λmel 17-1 gene product act on melanin biosynthesis&#39;s pathway distal to tyrosinase. Melanocytes preferentially express an mRNA species, Pmel 17, whose protein product cross reacted with anti-tyrosinase antibodies and whose expression correlated with the melanin content. The deduced protein structure has been analyzed and its chromosomal location in mouse and man has been mapped. The human Pmel 17 gene, designated D12S53E, maps to Chromosome 12, region 12pter-q21; and the mouse homologue, designated D12S53Eh, maps to the distal region of mouse Chromosome 10, a region also known to carry the coat color locus si (silver).
A personal medical records retrieval system that allows a person to access their personal medical records from a remote medical records database 24 hours a day, 365 days a years from locations throughout the world. The remote medical records database has an Internet website and the person has a personalized access code for viewing his medical records from the database over the Internet. The database has a Firewall security and privacy/pirating protection system. A personalized access code can only be obtained by becoming a subscribing member to the personal medical records retrieval system. A subscriber may also receive a Smart Health Card that has a small computer (in the form of a computer chip with a memory embedded in it) that contains a person&#39;s medical history that can be read on a card reader in a physician&#39;s office, in a hospital, in emergency vehicles and any other place that is equipped with a card reader. The subscriber also receives a medical passport into which is inserted the Smart Health Card and it further comprises a CD-ROM disc that has a person&#39;s complete medical records on it and the disc can be read on any PC or laptop computer with proper authorization.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine eliciting production of antibody exhibiting complement-mediated bactericidal activity and/or opsonic activity against Neisseria meningitidis serogroup B bacterium.  &lt;P&gt;SOLUTION: Molecular mimetics of a surface-exposed epitope on loop 4 of PorA of N. meningitidis serogroup B (MenB) P1.2 serosubtype and antibodies produced against the mimetics are disclosed. Peptide GNA33 containing the amino sequence QTP is also disclosed. The peptide can induce production of antibodies eliciting complement-mediated bactericidal activity and/or opsonic activity against Neisseria meningitidis serogroup B bacterium. Compositions containing such molecular mimetics or the antibodies thereto can be used to prevent MenB disease, as well as for diagnosis of MenB infection.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
A diagnostic method for assessing how a hypercholesterolemic person&#39;s serum cholesterol level will respond to a low total fat and saturated fat diet. The method involves defining a target cholesterol level, measuring a baseline level, feeding for a term of 3-25 days a NCEP Step I diet of which at least 50% of the caloric intake is provided by a fortified, low-fat nutritional product, and comparing the post term cholesterol level to the defined goal to see if the target is met. If the target is met, the person is predicted to respond to dietary intervention. If the target is not met, the person is deemed a non-responder and is considered for drug therapy. A fortified, low-fat nutritional product supplies in about 1000 kcal (i) 100% of the adult RDI for vitamins and minerals; and (ii) total fat, saturated fat and cholesterol levels that are at or below the levels specified for a Step II diet. Preferably the total fat comprises 25% or less of total calories; and the saturated fat and cholesterol maximum levels are less than about 2-3% of total calories in the case of saturated fat, and less than about 30-50 mg per 1000 kcal in the case of cholesterol.
PURPOSE:To obtain the titled plaster having remarkably improved transcutaneous absorption of the active component, by forming an acrylic sticking layer containing indomethacin and polyoxyethylene alkyl (phenyl) ether on a substrate. CONSTITUTION:An acrylic pressure-sensitive adhesive, preferably a copolymer of an alkyl acrylate having a &gt;=4C alkyl and a functional monomer having carboxyl or hydroxyl group in the molecule and/or vinyl acetate, is mixed with indomethacin and an auxiliary selected from polyoxyethylene alkyl ethers and polyoxyethylene alkylphenyl ethers, and the layer of said pressure-sensitive adhesive is applied to the surface of a substrate. The amount of indomethacin is 5-250mg per 1g of the polymer, and that of the auxiliary is 1-35pts.wt. per 100pts.wt of the polymer. The auxiliary is preferably liquid or pasty at 25 deg.C. The active component can be absorbed deep into the skin or in the blood.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a particulate having a medicinal function more excellent than that of a colloid made of a noble metal simple substance.  &lt;P&gt;SOLUTION: Each metal complex particulate has a particle diameter of 0.7 to 10 nm, and is substantially made of a metal complex, and, as the whole metal complex particulate, the electric charge is substantially controlled to zero. As the metal complex, a noble metal complex is preferably used. The metal complex in this invention is suitably used for medical use. The metal complex particulate can be produced by preparing an aqueous solution using a metal salt, ligands coordinated at metal ions comprised in the metal salt, a pH regulator and water, and stirring the aqueous solution while being held to a temperature of &gt;0 to 10°C.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention comprises N-dialkyl and N-diaralkyl phosphoryl homocystein thiolactones of the general formula: &lt;FORM:0903322/IV (b)/1&gt; in which R1 and R2 are alkyl or aralkyl radicals. They may be obtained by reacting homocystein thiolactone, or a salt thereof, e.g. its hydrohalide, with a phosphoryl halide of the formula (R1O)(R2O)P(O)X in which X is a halogen atom, preferably chlorine, in the presence of a tertiary amine as acid acceptor.  The reaction is preferably carried out in the presence of a solvent or diluent, especially one containing a hydroxyl group, e.g. an alcohol such as methanol or ethanol. Preferred reaction temperatures are from 0 to 80 DEG C. and it is particularly advantageous to work in an inert gas atmosphere, e.g. nitrogen.  The thiolactone ring in the product can easily be split open by the action of weak alkalis to form the corresponding N-dialkyl (or diaralkyl) phosphoryl homocysteins. Examples are given for the production of products of the above formula in which R1 and R2 are each ethyl and isopropyl respectively. The products have medicinal properties, e.g. in liver disorders, and have a protective effect against radiation.
PROBLEM TO BE SOLVED: To obtain a composition containing a deacetylated moxisylyte(DAM) as an active ingredient and useful for the treatment of acute urinary retention. SOLUTION: This deacetylated moxisylyte for the treatment of acute urinary retention contains 0.5-7.5% P/V DAM and a salt thereof as an active ingredient. And further, an aqueous solution usable for an intravenous administration thereof, is prepared by blending 0.01-0.1% P/V antioxidant, &lt;=50 vol.% organic solvent (e.g.; ethanol) based on the total amount of the composition and suitably a buffering agent to adjust at pH 5-7. The acute urinary retention is a disease apt to occur after any and all surgical operations. The DAM or salt thereof is used as a medicine for inducing the reduction of the contraction property of urinary tract. That is, by intravenous injection of the DAM, urinary bladder is emptied, and urination is made easy. As to the amount of administration, 5-50 mg is injected once daily, and it is preferable to continue the administration for 1-3 weeks.
1480175 Coated tablets NIPPON KAYAKU KK and HAYASHIBARA BIOCHEMICAL LABORATORIES INC 8 Oct 1975 [8 Oct 1974] 41271/75 Heading A5B Pharmaceutical preparations in the form of coated tablets prepared by the direct compression method comprise a pharmacologically active ingredient e.g. 2, 4&#39;-dimethyl-3- piperidinopropiophenone or bromelain and maltose are prepared by mixing a pharmacologically active ingredient with maltose, directly compressing the mixture into tablets and coating the tablets. The coating may be sugar or cellulose acetate phthalate. The preparation may further comprise a lubricant e.g. talc, silicon dioxide powder, magnesium stearate, stearic acid or palmitic acid; an adjuvant such as crystalline lactose, mannitol, sorbitol, calcium sulphate or anhydrous calcium phosphate; and/or a disintegrant e.g. corn starch, potato-starch, calcium carboxymethyl cellulose or hydroxy propyl starch.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition capable of inhibiting the light-induced peroxydation of an unsaturated lipid, in particular, a lipid of sebaceous origin.  &lt;P&gt;SOLUTION: The composition contains at least one kind of tocopherol and at least one of photocatalytic metal oxides. A metal-inactivating complexing agent can be contained therein. The composition can be used as a cosmetic and/or dermatological composition. The composition can also be used for preservation of another product.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
A transdermal therapeutic system using a subsaturated matrix is provided having improved approved release characteristics. Reinforcing means preferably in the form of a fabric are embedded in the upper surface of the subsaturated matrix. At least a portion of the reinforcing means is selected such that the active agent to be delivered to the skin has a solubility, Cr therein which is lower than the initial solubility Co of the agent in the matrix. In addition, the relationship between the diffusion coefficients of the agent in the matrix Dm and the portion of reinforcing means Dr and the solubilities is given by the relationship: DrxCr&lt;DmxCo. In operation the agent dissolved in the reinforcing means acts as a secondary reservoir improving the release characteristics of the system. Specific embodiments of the invention are particularly adapted for scrotal and labial delivery of drugs such as testosterone and progesterone.
An interactive platform providing health care prevention is provided. The platform includes a plurality of doctor interfaces, each doctor interface being associated with a doctor or other health care provider participating in the platform, patient interfaces coupled to peripherals measuring and determining patient parameters associated with the patients&#39; health, said patient interfaces receiving, patient information, instructions, data from peripherals, and so on. In one embodiment, each patient interface is associated with a particular patient. In another embodiment, an intermediate assistant is provided with a patient interface adapted to provide information to and receive information related to several patients. A master server in communication with the doctor and patient interfaces and adapted to collect information and present information through said interfaces. Rules and criteria are used by the master server to monitor the patients&#39; parameters, send reminders to the patient interfaces, and multi-level alarms to the doctor interfaces and devices of third parties when the patient parameters do not meet criteria selected by the individual doctors for their patients.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means which can be effectively and beneficially applied in a wide range of various situations requiring stimulation, regulation or induction of immunological reaction.  &lt;P&gt;SOLUTION: The present invention relates to a pharmaceutical composition comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention, the above problem was solved by the fact that introduction of the pharmaceutical composition into vertebrates achieved regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical composition is useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit (e.g. sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity).  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention provides immunogenic compositions for mucosal and parenteral applications that consist of (1) single or multiple non conjugated bacterial polysaccharide and (2) potent adjuvants. Plain polysaccharides or olygosaccharides are preferred without excluding the addition of potent adjuvants to conjugated polysaccharides. It is preferred that adjuvants were AFCox (Adjuvant Finlay Cocleate family x) or AFPLx (Proteolyposome family x). Mucosal route is preferred without excluding the parenteral one or combinations of them. The invention also provides immunogenic compositions a) a capsular sacaride antigen from serogroup C or serogroup A from  Neisseria meningitidis,  b) adjuvants AFPL1 adsorbed unto aluminum by parenteral route or non adsorbed AFPL1 or AFCo1 by nasal route and c) the application of two simultaneous parenteral and mucosal &#39;priming&#39; with any of the potent adjuvants formulated with the afore mentioned antigens. The use of potent adjuvants formulated with non conjugated polysaccharides enhance mucosal and systemic immune response, polarizing the independent thymus response of polysaccharides to a dependent thymus response with a pattern Th1, cellular, which ensures its functionability in young children and inducing immune memory without needing convalent conjugation.
PURPOSE:To prepare chewing gum having a cleaning effect on teeth, by replacing partially saccharides with cellulose and fats and oils. CONSTITUTION:15-40wt% based on chewing gum of cellulose having a particle size of &gt;=100mesh and 3-10wt% based on celluose of cacao butter, palm oil, coconut oil, etc. having a melting point of 20-48 deg.C are added to chewing gum. To compensate for the reduction in amount used of the saccharides, a sweetener such as saccharin, stevioside, etc. is added to it. Raw materials except these substances are raw materials for common chewing gum, and the raw materials are blended to give chewing gum.